PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Recombinant Technologies, LLC

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Recombinant Technologies Announces A Promising New Small Molecule for Alzheimers Disease - Recombinant Technologies, a start up firm, has identified a small molecule therapeutic to treat Alzheimer's Disease. The therapy, in its initial stages of clinical development, is able to bind and eliminate the toxic abeta proteins in AD model mice
Recombinant Technologies Announces A Promising New Small Molecule for Alzheimers Disease

 

NewswireToday - /newswire/ - Cheshire, CT, United States, 2012/08/17 - Recombinant Technologies, a start up firm, has identified a small molecule therapeutic to treat Alzheimer's Disease. The therapy, in its initial stages of clinical development, is able to bind and eliminate the toxic abeta proteins in AD model mice.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Recombinant Technologies (RT), a start up biotechnology company based in Cheshire, CT, has been involved in the discovery of a new small molecule therapy to treat Alzheimer’s Disease. Being a 100% privately held firm, RT has been successful in acquiring grants from National Institute on Aging, a branch of National Institutes of Health of the Department of Health and Human Services (DHHS), Bethesda, Maryland. Recently, Connecticut Innovations Inc, a quasi government agency based in Rocky Hill, CT, has awarded RT with a matching grant to expedite the research efforts.

Alzheimer’s Disease (AD) is a neurodegenerative disease that causes dementia among the elderly population, affecting about 30 million people worldwide. In industrialized nations, AD is the fourth most common cause of death. It is expected that the number of affected people will double over the next 20 years. AD is a growing problem that takes a monetary, emotional and human toll.

The treatment of AD is an unmet medical need for which no therapies have been shown to work. RT’s research over the past decade has led to a drug molecule. RT has been able to get ‘proof of concept’ in an animal model of AD by this therapeutic drug utilizing the funds so far. “The drug molecule is a promising candidate for Alzheimer’s since it has been shown to complex and eliminate the toxic abeta molecules toxic molecules that deposit in the brain causing memory loss and other degenerative symptoms of AD] from the system. In addition the drug is shown to have reduced abeta levels in the brain of treated AD model mice. Memory parameters have improved in the treated mice. The next step is to test the safety and kinetics of this drug molecule during long term consumption using animal models”, says Pazhani Sundaram, the Founder-President of the firm, who was trained at Yale for over a decade prior to starting this company in 2000. He said the advantages of working with this molecule is that it is a non-immune based, biologically tolerated small molecule that is yet to show any undesirable side effects. Numerous immune based monoclonal antibodies were discontinued during human clinical trials because of their potent side effects and mortality rates.

Dr. Sundaram graduated from the University of Madras, India where his PhD thesis work was on the research and development of a herbal medicine to treat coronary heart disease. The drug he researched on is approved in India and USA. He says he is excited to be able to come up with this new therapeutic candidate for Alzheimer’s. He further said the RT is exploring many avenues to expedite the completion of the research phase and move on to the clinical trials potentially in partnership with an established biopharmaceutical company such as Pfizer, Bristol Meyers or J & J and that he will make the move when the terms and time are appropriate. Two publications in Current Alzheimers Research and International Journal of peptide Research Therapeutics detail the scientific findings from RT. RT own the IP rights to the therapy (patent pending with USPTO)

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Recombinant Technologies, LLC

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Recombinant Technologies Announces A Promising New Small Molecule for Alzheimers Disease

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Pazhani Sundaram PhD - RecombTech.com 
203-271-3125 reply[.]recombtech.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Recombinant Technologies, LLC securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Recombinant Technologies, LLC / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)